What Resverlogix does

Resverlogix Corp. is a late-stage clinical biotechnology company headquartered in Calgary, Alberta, Canada, founded in 2001 by Donald McCaffrey and Norman Wong. The company is publicly traded on the Toronto Stock Exchange under the ticker RVX and operates with a small team (estimated 11–50 employees). It is pre-revenue and has not yet commercialized any product, instead concentrating resources on clinical development of its lead compound.

The company's core asset is apabetalone (RVX-208), a first-in-class, oral, selective inhibitor of bromodomain and extra-terminal (BET) proteins, with a mechanism that modulates gene expression linked to cardiovascular, inflammatory, metabolic, and fibrotic pathways. Apabetalone has been evaluated in over 4,000 subjects across clinical studies, including the completed Phase 3 BETonMACE trial in 2,425 participants with recent acute coronary syndrome, type 2 diabetes, and low HDL-C. The compound has received FDA Breakthrough Therapy Designation, and the company has expanded clinical investigation into severe COVID-19, pulmonary arterial hypertension (PAH), Fabry disease, and chronic kidney disease (BETonRENAL program). A wholly-owned subsidiary, Zenith Epigenetics Ltd., extends the BET inhibition platform into oncology indications.

Resverlogix's business model is currently capital-raise-driven rather than revenue-generating, with funding sourced through equity issuances, debentures, and strategic investments. Commercialization planning is in early stages via a partnership with EVERSANA, while Shenzhen Hepalink Pharmaceutical Group functions simultaneously as a significant shareholder (~39.55%) and strategic investor supporting global development. The company's addressable patient population, if apabetalone is approved, spans cardiovascular disease, diabetes, CKD, and rare/orphan indications, positioning it as a potential multi-indication chronic disease therapeutics provider.

Name

Resverlogix

Legal name

Resverlogix Corp.

Website

https://resverlogix.com

Company type

Public

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

Resverlogix is a Calgary-based clinical-stage biotechnology company developing apabetalone (RVX-208), a first-in-class oral BET inhibitor for cardiovascular, metabolic, renal, and inflammatory diseases, with FDA Breakthrough Therapy Designation.

Ownership category

akta.pro rank

Product category

Cardiovascular Pharmaceuticals

NAICS

Medicinal and Botanical Manufacturing (325411), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Cardiometabolic & Other Systemic Gene Therapies (HLAAACAI), Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Epigenetic therapeutics
• BET inhibitors
• Cardiovascular pharmaceuticals
• Clinical-stage biotechnology
• Chronic disease drugs

Headquarters

HQ city

Calgary

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical-stage biotechnology company. Once apabetalone receives regulatory approval, the company plans to commercialize the drug through traditional pharmaceutical distribution channels, generating revenue from product sales.
2. Potential Licensing/Partnership Revenue: The company may pursue licensing agreements or strategic partnerships for global commercialization of apabetalone in various territories or therapeutic indications.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Resverlogix develops apabetalone (RVX-208), a first-in-class selective BET (bromodomain and extra-terminal) inhibitor administered as a twice-daily oral tablet that regulates disease-associated gene expression at the epigenetic level. The drug candidate is in late-stage clinical evaluation for high-risk cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, vascular dementia, and post-COVID-19 conditions.

Product overview

Resverlogix is a late-stage clinical biotechnology company developing a single lead product, apabetalone (RVX-208), which is a first-in-class selective BET inhibitor epigenetic therapy. Apabetalone is supported by multiple clinical programs including the Phase 3 BETonMACE trial for cardiovascular outcomes, the planned BETonRENAL trial for renal disease, a COVID-19 clinical trial program, and the APPRoAcH-p pilot study for pulmonary arterial hypertension. The company operates with a focused pipeline strategy centered exclusively on apabetalone across multiple therapeutic indications.

Differentiator

Problem solved

Functional benefit

Brands

• Apabetalone (RVX-208): Lead cardiovascular drug candidate - a selective BET (bromodomain and extra-terminal) inhibitor for treating cardiovascular disease, diabetes, chronic kidney disease, and other chronic conditions.
• BETonMACE

Products and services

• Apabetalone (RVX-208) Apabetalone is a first-in-class, selective BET (bromodomain and extra-terminal) inhibitor that works at the epigenetic level to regulate disease-causing genes. It is administered as a twice-daily tablet and is in late-stage clinical evaluation for high-risk cardiovascular disease, type 2 diabetes mellitus, chronic kidney disease, vascular dementia, and other chronic conditions.

Quantifiable outcome

• Demonstrated reduction in Major Adverse Cardiac Events (MACE) including cardiovascular death, non-fatal myocardial infarction, and stroke in BETonMACE Phase 3 trial participants
• +3 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and strategic.

• QIMR Berghofer Medical Research InstitutecoreStrategic or Co-development Partner · 3 March 2021Collaborative research partnership with QIMR Berghofer Medical Research Institute in Brisbane, Australia to study apabetalone's effects on COVID-19. Research led by Associate Professor James Hudson demonstrated that apabetalone treatment reduces SARS-CoV-2 infectivity and prevents cardiac dysfunction in cytokine-storm models. Results published in Cell journal.
• EVERSANAstrategicStrategic or Co-development PartnerResverlogix discussed partnership with EVERSANA on commercial innovation, with executives from both companies participating in a PharmaVOICE webinar on next-generation commercialization. EVERSANA is a commercialization partner for the pharmaceutical industry.
• Quebec Heart and Lung Institute - Laval UniversitycoreStrategic or Co-development Partner$2.9 million research project led by academic collaborators at Quebec Heart and Lung Institute, Laval University, to research apabetalone's potential for pulmonary arterial hypertension. Project received prestigious funding from Canadian Institutes of Health Research (CIHR) matched by Resverlogix.

Scale indicators6 records

Recent moves1 record

Expansion highlights6 records

Broad incumbents

• Amarin Corporation: Specialty pharmaceutical company focused on cardiovascular disease, commercializing Vascepa (icosapent ethyl) for residual cardiovascular risk reduction. Comparable as a focused cardiovascular player targeting patients with persistent risk despite statin therapy, directly addressing the same unmet need as apabetalone.
• AbbVie: Large pharmaceutical company with an active BET inhibitor (VLS-101 / vecabrutinib successor) and broader epigenetics program via its ImmunoGen and Harpoon acquisitions. Relevant as a major incumbent with competing BET inhibitor programs in hematologic cancers that may eventually overlap with Resverlogix's chronic-disease pipeline.
• Ionis Pharmaceuticals: Established antisense oligonucleotide platform company with a substantial cardiovascular pipeline including pelacarsen (Lp(a) reduction) partnered with Novartis. Comparable as a chronic-disease RNA-targeting drug developer addressing residual cardiovascular risk.
• Bristol-Myers Squibb: Global biopharmaceutical company with active BET inhibitor (BMS-986158) and bromodomain programs in oncology and immuno-oncology. Relevant as a major incumbent investing in the same BET inhibition mechanism that Resverlogix is pioneering in chronic cardiovascular and renal disease.

Emerging players

• Forma Therapeutics: Clinical-stage biopharmaceutical company developing transformative therapeutics for rare hematologic diseases and cancers, with a pipeline including BET inhibitors and other epigenetic modulators. Acquired by Novo Nordisk in 2022. Comparable as an emerging player in BET inhibition and epigenetic drug development.
• Esperion Therapeutics: Late-stage pharmaceutical company developing oral, once-daily LDL-cholesterol lowering therapies (Nexletol/Nexlizet). Comparable as a focused clinical-to-commercial cardiovascular lipid-management company competing for similar high-risk patient populations.
• Lexicon Pharmaceuticals: Small-cap biopharmaceutical company developing therapies for cardiovascular, metabolic, and neuropathic conditions. Comparable as a similarly-sized clinical-stage biotech focused on cardiometabolic indications, though with a broader small-molecule pipeline.

Direct peers

• Oryzon Genomics: Clinical-stage epigenetics company developing LSD1 inhibitors for oncology and CNS disorders. Comparable to Resverlogix as a small-cap, Europe-based clinical-stage epigenetic therapy developer with a single-platform focus on chromatin-modifying enzymes.
• Constellation Pharmaceuticals: Was a clinical-stage developer of BET inhibitors and other epigenetics-targeted oncology therapies (acquired by MorphoSys in 2021). Highly comparable as a direct competitor developing BET-bromodomain inhibitors, though Constellation's focus was hematology/oncology versus Resverlogix's cardiovascular focus.
• Syros Pharmaceuticals: Clinical-stage biopharmaceutical company developing small-molecule medicines that control gene expression via epigenetic mechanisms. Directly comparable to Resverlogix as a focused epigenetic therapy developer, though Syros's primary focus is oncology rather than chronic cardiovascular disease.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/Resverlogix_RVX
• LinkedInlinkedin.com/company/resverlogix-corp-

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds13 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Resverlogix